- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Investigators Set Sights on Novel Agents Following Negative Studies in Relapsed Small Cell Lung Cancer
July 28th 2023, 6:56pm
International Lung Cancer Congress
New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines.
Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC
July 27th 2023, 11:43pm
International Lung Cancer Congress
Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.
Dr Kim on Improving Representation in Clinical Trials
July 27th 2023, 10:57pm
International Lung Cancer Congress
Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.
Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC
July 27th 2023, 9:20pm
International Lung Cancer Congress
Positive event-free survival data from the phase 3 AEGEAN, NEOTORCH, and KEYNOTE-671 trials add further evidence to the benefit of perioperative immunotherapy in early-stage non–small cell lung cancer but have yet to show clear biomarkers of response beyond PD-L1.
OS Data Reinforce Adjuvant Osimertinib as Standard of Care for Resectable EGFR+ NSCLC
July 27th 2023, 7:50pm
International Lung Cancer Congress
Overall survival analysis from ADAURA bolsters the already impressive disease-free survival data for patients with EGFR-mutant non–small cell lung cancer.
Continued Emergence of Targeted Therapies for EGFR+ NSCLC Underscores Importance of Molecular Testing
July 27th 2023, 5:40pm
International Lung Cancer Congress
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer
July 25th 2023, 9:35pm
Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.
Advances in Early-Stage Breast Cancer Pull Biology and Biomarkers Into Focus
July 25th 2023, 2:00pm
As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.
ADCs and Radiotherapeutics Represent Novel Treatment Methods in RCC
July 15th 2023, 10:00am
The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.
Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups
July 14th 2023, 9:31pm
The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.
Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC
July 14th 2023, 9:21pm
Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.
Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC
July 14th 2023, 8:59pm
Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.
Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC
July 14th 2023, 8:46pm
Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.
Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC
July 14th 2023, 8:25pm
Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.
Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC
July 14th 2023, 5:55pm
Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.
Dr Ged on Interim Data With Olaparib in DNA Repair Gene–Mutated mRCC
July 14th 2023, 5:47pm
Yasser Mohamed Ali Ged, MBBS, discusses the phase 2 ORCHID trial (NCT03786796).
Dr Choueiri on Trials in Progress in Advanced Renal Cell Carcinoma
July 14th 2023, 5:44pm
Toni K. Choueiri, MD, discusses ongoing trials in advanced renal cell carcinoma.
Dr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCC
July 14th 2023, 5:41pm
David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).
Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC
July 14th 2023, 3:23pm
Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.
Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages
July 14th 2023, 2:50pm
Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.